Weight Regain After Stopping Semaglutide: When It Starts and Why

The biggest misconception: weight regain means the treatment failed

The most common misunderstanding about stopping semaglutide is that regaining weight means something went wrong, either with the medicine or with the person taking it. It did not. The STEP 1 trial, published in the New England Journal of Medicine, followed participants for a year after the treatment phase ended. Average body weight had returned towards baseline by month 12, with roughly two-thirds of the lost weight regained. This happened in a controlled trial population under observation, not through lack of discipline.

Semaglutide reduces appetite, slows how quickly food leaves the stomach, and shifts the body's perception of fullness. Stop the medicine and those effects stop with it. Hunger creeps back, often to levels higher than before treatment started, because the underlying biology that was being managed is no longer being managed. Weight regain after stopping semaglutide is the expected pharmacological outcome, not a relapse into bad habits. Understanding that distinction matters — both for people deciding whether to stop and for those who already have.

If you want to understand what else changes when you stop Wegovy, including mood, appetite and energy patterns, the picture is worth reading before making a decision.

How quickly does regain actually begin?

The short answer: sooner than most people expect. Semaglutide has a half-life of roughly seven days, which means drug concentrations drop meaningfully within the first two weeks after the last injection. Appetite tends to return before the scales move, which is why many people notice hunger increasing before any weight change registers. You can read more about how long semaglutide stays active in the body after stopping for the pharmacokinetic detail.

By week four to six, measurable weight change is common for most people. The rate of regain tends to be fastest in the first few months, then slows. STEP 1 extension data suggest the trajectory is not uniform: an initial rapid phase gives way to a slower one, though total regain over twelve months is still substantial. A related question many people ask is precisely when the first weight increase tends to appear after the last dose, the answer depends partly on dose history and how abruptly treatment stopped.

For people who were on a lower dose or who had not yet reached the maintenance phase, the rebound may be gentler, though not absent. Dose and duration of treatment appear to influence the pace, if not the direction, of regain.

Can anything reduce the rebound?

Yes, though no strategy eliminates it entirely without ongoing treatment. The evidence points to a few practical priorities for the period immediately after stopping.

Protein intake is the most consistently cited factor. Adequate dietary protein in the weeks after stopping helps preserve lean muscle mass, which supports metabolic rate. Resistance training compounds this effect. Both are worth building into a plan before the last injection rather than after weight has already returned. The NHS medicines information for semaglutide notes that the medicine is intended to accompany dietary changes and increased physical activity, not replace them, which matters especially as treatment ends.

Stopping gradually rather than abruptly, where clinically appropriate, may also soften the transition, though any titration plan should come from a prescriber. The question of whether keeping weight off after Wegovy is realistically possible is worth exploring separately, as the honest answer is nuanced. Some people do maintain a meaningful portion of their loss, particularly those who have made durable changes to eating patterns and activity. Most do not maintain all of it without continued treatment.

Cost is a real factor in these decisions. If you are weighing up the cost of continuing against the cost of stopping and regaining, our guide to Wegovy pricing in the UK sets out what you are actually comparing.

What this means for long-term planning

The NHS describes weight as a chronic condition. NICE's guidance on semaglutide (Wegovy) does not define a maximum duration based on arbitrary timelines, it recommends reviewing continuation based on whether the medicine is still producing clinical benefit, and specifically notes considering stopping if less than 5% of starting weight has been lost after six months on the full maintenance dose. The framing is clinical, not calendar-based.

For people considering stopping, the practical checklist before the last dose matters more than the date itself. What dietary habits are in place? Is there an exercise routine that doesn't depend on appetite suppression to sustain it? Has a prescriber been involved in the decision, rather than it happening because a delivery wasn't reordered one Tuesday before the school run? The weeks immediately after stopping are the highest-risk period for rapid regain, and having a plan for them makes a measurable difference.

If you are weighing options (whether to continue, switch to a different treatment, or stop entirely) a prescriber can review your position without pressure. You can explore practical approaches to minimising regain after Wegovy and, if you want clinical guidance on your own situation, our team at nume's consultation service can help you think it through.